

Listing of the Claims:

This listing of claims will replace all prior versions and listing of the claims in the application.

1-27. (cancelled)

28. (new) A method for identifying a leukemia of T cell, B cell, or myeloid lineage in a human subject comprising the steps of:

providing a single assay device comprising a solid support having an array of immunoglobulin molecules immobilized in discrete regions on the solid support, wherein the immunoglobulin molecules are specific for the single cell surface marker antigens of CD3, CD4, CD8, CD14, CD19, and CD56;

contacting a biological sample containing leukocytes obtained from a human subject with the assay device;

allowing leukocytes in the biological sample to bind to the immunoglobulin molecules on the solid support via cell surface marker antigens on the leukocytes to form a pattern of binding on the array; and

determining the relative scale of the pattern of binding with which the cell surface marker antigens on the leukocyte have bound to the immunoglobulin molecules on the array, wherein the relative scale of the pattern of binding on the array distinguishes leukemia of T cell, B cell, or myeloid lineage in the subject.

29. (new) The method according to claim 28, wherein the solid support further contains at least one immunoglobulin specific for single cell surface marker antigens of a T cell, B cell, or myeloid lineage selected from the group consisting of CD2, CD5, CD7, CD9, CD10, CD11b, CD11c, CD13, CD15, CD16, CD20, CD21, CD22, CD23, CD24, CD25, CD33, CD34, CD36, CD37, CD38, CD41, CD42a, CD44, CD44v3-10, CD44v6, CD45, CD45RA, CD45RO, CD52, CD57, CD60, CD61, CD64, CD71, CD79a, CD79b, CD80, CD95, CD103, CD117, CD122, CD134, CD138, CD154, Kappa, Lambda, GPA, HLA-DR, KOR, FMC7, Anti-hlg, and Anti-Ig.

30. (new) The method according to claim 28, wherein the solid support further contains 39 immunoglobulins specific for single cell surface marker antigens selected from the group consisting of CD2, CD5, CD7, CD9, CD10, CD11b, CD11c, CD13, CD15, CD16, CD20, CD21, CD22, CD23, CD24, CD25, CD33, CD34, CD36, CD37, CD38, CD41, CD42a, CD44, CD44v3-10, CD44v6, CD45, CD45RA, CD45RO, CD52, CD57, CD60, CD61, CD64, CD71, CD79a, CD79b, CD80, CD95, CD103, CD117, CD122, CD134, CD138, CD154, Kappa, Lambda, GPA, HLA-DR, KOR, FMC7, Anti-hlg, and Anti-Ig.

31. (new) The method according to claim 28 wherein the solid support further contains 41 immunoglobulins specific for single cell surface marker antigens selected from the group consisting of CD2, CD5, CD7, CD9, CD10, CD11b, CD11c, CD13, CD15, CD16, CD20, CD21, CD22, CD23, CD24, CD25, CD33, CD34, CD36, CD37, CD38, CD41, CD42a, CD44, CD44v3-10, CD44v6, CD45, CD45RA, CD45RO, CD52, CD57, CD60, CD61, CD64, CD71,

CD79a, CD79b, CD80, CD95, CD103, CD117, CD122, CD134, CD138, CD154, Kappa, Lambda, GPA, HLA-DR, KOR, FMC7, Anti-hlg, and Anti-Ig.

32. (new) The method according to claim 28, wherein the solid support further contains 42 immunoglobulins specific for single cell surface marker antigens selected from the group consisting of CD2, CD5, CD7, CD9, CD10, CD11b, CD11c, CD13, CD15, CD16, CD20, CD21, CD22, CD23, CD24, CD25, CD33, CD34, CD36, CD37, CD38, CD41, CD42a, CD44, CD44v3-10, CD44v6, CD45, CD45RA, CD45RO, CD52, CD57, CD60, CD61, CD64, CD71, CD79a, CD79b, CD80, CD95, CD103, CD117, CD122, CD134, CD138, CD154, Kappa, Lambda, GPA, HLA-DR, KOR, FMC7, Anti-hlg, and Anti-Ig.

33. (new) The method according to claim 28, wherein the solid support further contains 44 immunoglobulins specific for single cell surface marker antigens selected from the group consisting of CD2, CD5, CD7, CD9, CD10, CD11b, CD11c, CD13, CD15, CD16, CD20, CD21, CD22, CD23, CD24, CD25, CD33, CD34, CD36, CD37, CD38, CD41, CD42a, CD44, CD44v3-10, CD44v6, CD45, CD45RA, CD45RO, CD52, CD57, CD60, CD61, CD64, CD71, CD79a, CD79b, CD80, CD95, CD103, CD117, CD122, CD134, CD138, CD154, Kappa, Lambda, GPA, HLA-DR, KOR, FMC7, Anti-hlg, and Anti-Ig.

34. (new) The method according to claim 28, wherein the solid support further contains 52 immunoglobulins specific for single cell surface marker antigens selected from the group consisting of CD2, CD5, CD7, CD9, CD10, CD11b, CD11c, CD13, CD15, CD16, CD20, CD21, CD22, CD23, CD24, CD25, CD33, CD34, CD36, CD37, CD38, CD41, CD42a, CD44, CD44v3-10, CD44v6, CD45, CD45RA, CD45RO, CD52, CD57, CD60, CD61, CD64, CD71, CD79a, CD79b, CD80, CD95, CD103, CD117, CD122, CD134, CD138, CD154, Kappa, Lambda, GPA, HLA-DR, KOR, FMC7, Anti-hlg, and Anti-Ig.

35. (new) The method according to claim 29, wherein the relative pattern of binding is detected microscopically, biochemically, histochemically or immunologically.

36. (new) The method according to claim 35, wherein the relative pattern of binding is detected microscopically.

37. (new) The method according to claim 29 wherein the immunoglobulins are monoclonal antibodies.

38. (new) The method according to claim 29 wherein the immunoglobulins are polyclonal antibodies.

39. (new) The method according to claim 29 further comprising microscopic analysis of cellular morphology of the leukocytes.

40. (new) The method according to claim 29 further comprising histochemical, biochemical or immunological analysis.